Longevity biotech: a different strategy The fastest way to bring longevity drugs to market may be extremely difficult but fundamentally simple: target aging
The history of longevity biotech What we've learned from more than 30 years of a story that has repeated itself time and again
Longevity for pets: from zero to one Targeting deregulated nutrient-sensing and mitochondrial dysfunction to bring the first product to market that increases healthy lifespan in companion animals
A mental model for aging drugs market readiness Looking with a product mindset at the likelihood of aging interventions making their way from lab to real-world impact